Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed

Permanent URI for this communityhttps://acikerisim2.beykoz.edu.tr/handle/20.500.12879/1

Browse

Now showing 1 - 3 of 3

Applications of Exosome Vesicles in Different Cancer Types as Biomarkers
(Bentham Science Publishing Ltd, 2024) Ihlamur, Murat; Kelleci, Kubra; Zengin, Yagmur; Allahverdiyev, M. Adil; Abamor, Emrah Sefik
One of the biggest challenges in the fight against cancer is early detection. Early diagnosis is vital, but there are some barriers such as economic, cultural, and personal factors. Considering the disadvantages of radiological imaging techniques or serological analysis methods used in cancer diagnosis, such as being expensive, requiring expertise, and being time-consuming, there is a need to develop faster, more reliable, and cost-effective diagnostic methods for use in cancer diagnosis.Exosomes, which are responsible for intercellular communication with sizes ranging from 30-120 nm, are naturally produced biological nanoparticles. Thanks to the cargo contents they carry, they are a potential biomarker to be used in the diagnosis of cancer. Exosomes, defined as extracellular vesicles of endosomal origin, are effective in cancer growth, progression, metastasis, and drug resistance, and changes in microenvironmental conditions during tumor development change exosome secretion. Due to their high cellular activity, tumor cells produce much higher exosomes than healthy cells. Therefore, it is known that the number of exosomes in body fluids is significantly rich compared to other cells and can act as a stand-alone diagnostic biomarker. Cancer-derived exosomes have received great attention in recent years for the early detection of cancer and the evaluation of therapeutic response.In this article, the content, properties, and differences of exosomes detected in common types of cancer (lung, liver, pancreas, ovaries, breast, colorectal), which are the leading causes of cancer-related deaths, are reviewed. We also discuss the potential utility of exosome contents as a biomarker for early detection, which is known to be important in targeted cancer therapy.
Design and Simulation of the Microcantilever Biosensor for MITF Antigen and D5 Monoclonal Antibody Interaction Finite Element Analysis, and Experimental
(Bentham Science Publishing Ltd, 2024) Akcali, Pelin; Kelleci, Kubra; Ozer, Sevil
Background Biosensors and MEMS have witnessed rapid development and enormous interest over the past decades. Constant advancement in diagnostic, medical, and chemical applications has been demonstrated in several platforms and tools. In this study, the analytical and FEA of the microcantilever used in biomolecular analyses were compared with the experimental analysis results.Methods In this study, MITF antigen, which is a melanoma biomarker, and anti-MITF antibody (D5) were selected as biomolecules. A MEMS-type microcantilever biosensor was designed by functionalizing the AFM cantilever by utilizing the specific interaction dynamics and intermolecular binding ability between both molecules. Surface functionalization of cantilever micro biosensors was performed by using FEA. The stress that will occur as a result of the interactions between the MITF-D5 has been determined from the deviation in the resonant frequency of the cantilever.Results It has been found that the simulation results are supported by analytical calculations and experimental results.Conclusion The fact that the results of the simulation study overlap with the experimental and mathematical results allows us to get much cheaper and faster answers compared to expensive and time-consuming experimental approaches.
The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-Generation Inhibitors and Approaches
(Bentham Science Publishing Ltd, 2024) Ihlamur, Murat; Akgul, Busra; Zengin, Yagmur; Korkut, Senay Vural; Kelleci, Kubra; Abamor, Emrah Sefik
mTOR is a serine/threonine kinase that plays various roles in cell growth, proliferation, and metabolism. mTOR signaling in cancer becomes irregular. Therefore, drugs targeting mTOR have been developed. Although mTOR inhibitors rapamycin and rapamycin rapalogs (everolimus, rapamycin, temsirolimus, deforolimus, etc.) and new generation mTOR inhibitors (Rapalink, Dual PI3K/mTOR inhibitors, etc.) are used in cancer treatments, mTOR resistance mechanisms may inhibit the efficacy of these drugs. Therefore, new inhibition approaches are developed. Although these new inhibition approaches have not been widely investigated in cancer treatment, the use of nanoparticles has been evaluated as a new treatment option in a few types of cancer.This review outlines the functions of mTOR in the cancer process, its resistance mechanisms, and the efficiency of mTOR inhibitors in cancer treatment. Furthermore, it discusses the next-generation mTOR inhibitors and inhibition strategies created using nanoparticles.Since mTOR resistance mechanisms prevent the effects of mTOR inhibitors used in cancer treatments, new inhibition strategies should be developed. Inhibition approaches are created using nanoparticles, and one of them offers a promising treatment option with evidence supporting its effectiveness.

Browse

Browsing Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed by Publisher "Bentham Science Publishing Ltd"